Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JANX014 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on JANX014, a putative double-masked tumor activated T-cell engager (TRACTr) targeting PSMA (May 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JANX014 | JANX-014|JANX 014 | Limited information is currently available on JANX014, a putative double-masked tumor activated T-cell engager (TRACTr) targeting PSMA (May 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07545811 | Phase I | JANX014 | Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |